Otsuka Pharmaceutical Development And Commercialization recalls

Otsuka Pharmaceutical Development And Commercialization appears in 2 official U.S. recall notices indexed by RecallRadar, most recently on 2018-10-10.

Company names are normalized from agency data (legal suffixes removed), so related firms may appear under separate pages.

• treatNOW ABILIFY (aripiprazole) / ABILIFY MAINTENA 400-mg (aripiprazole) for extended release injectable suspension
  FDA Drug · Class III · 2018-10-10 · Otsuka Pharmaceutical Development And Commercialization
• treatNOW ABILIFY (aripiprazole) and ABILIFY MAINTENA (aripiprazole) 400MG for extended release injectable suspension
  FDA Drug · Class III · 2018-10-10 · Otsuka Pharmaceutical Development And Commercialization